<DOC>
	<DOCNO>NCT02496286</DOCNO>
	<brief_summary>This study evaluate safety efficacy intraperitoneal administration Bevacizumab prevent recurrence malignant ascites . Ten patient receive intraperitoneal Bevacizumab 200 mg 250 ml normal saline infusion every two week six week , maximum three treatment .</brief_summary>
	<brief_title>Feasibility Study Intraperitoneal Bevacizumab Palliation Intractable Malignant Ascites</brief_title>
	<detailed_description>This protocol describe pilot study ass whether intraperitoneal Bevacizumab infusion safe improves time repeat paracentesis . In patient non-draining malignant peritoneal effusion , publish data suggests average time repeat paracentesis malignant ascites 10-13 Days . The investigator ' treatment consider potentially efficacious median time repeat paracentesis great 14 day .</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients include case : Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) ≤ 2 Participants must 18 year age old Have ascites malignant disease Have symptom relate ascites Ascites Index 0.05 ( AI ˃ 0.05 ) Be English speaking patient interpreter available Be able understand comply study requirement implication offlabel use intraperitoneal Bevacizumab Have least two paracentesis within last 4 week Patients exclude case : Ascites due nonmalignant cause Concurrent treatment systemic chemotherapy realistic chance control ascites Concurrent treatment intraperitoneal Bevacizumab life expectancy le 2 week A history bowel perforation fistula Symptoms sign suggestive bacterial peritonitis Child 's C cirrhosis Uncontrolled hypertension Surgery within 28 day catheter treatment Evidence coagulopathy Symptoms suggestive bowel obstruction Major surgery , open biopsy significant traumatic injury within seven ( 7 ) day first study drugincluding neurosurgery . Inability complete inform consent process adhere protocol treatment plan followup requirement . Concurrent severe illness active infection , psychiatric illness/social situation would limit safety compliance study requirement Patients pregnant lactating ( female childbearing potential must negative pregnancy test prior participation ) Patients preexist 3 + great urine dipstick reading proteinuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Necessary paracentesis symptom control</keyword>
</DOC>